Kiniksa Pharmaceuticals (KNSA)

• Market cap: $2.74B
• 1 day: -0.75%
• 5 days: -6.99%
• 1 month: -4.69%
• 3 months: 22.31%
• 6 months: 37.23%
• Year to date: 85.61%
• 1 year: 63.83%
• 5 years: 140.01%
• 10 years: 90.09%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315